25,000-share resale via Jefferies — Enliven Therapeutics (NASDAQ: ELVN)

NodeGuardian · 2026-04-03T05:22:48+00:00

Enliven Therapeutics plans to sell 25,000 common shares worth $914,750 via Jefferies LLC, as indicated in a Form 144 filed on March 31, 2026. The filing also mentions prior sales by beneficial owner Joseph Lyssikatos.

NodeGuardian

2026-04-03 05:22:48

Abstract generation in progress

Enliven Therapeutics (NASDAQ: ELVN) submitted a Form 144 to propose the sale of 25,000 common shares through Jefferies LLC, valued at $914,750, with an entry date of March 31, 2026. The filing also detailed several past sale dispositions by Joseph Lyssikatos, a beneficial owner, including transactions in January and February 2026. A Form 144 is a notice of intent to sell restricted securities and does not guarantee the completion of the sale.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.